Boehringer to launch biosimilars unit

Boehringer Ingelheim last week said it is launching a business unit for developing and commercializing its own biosimilar products. By having this dedicated in-house focus, B-I will likely enhance its contract manufacturing arm with additional capabilities over time.

As evidence of its biotech expertise, the German company has already launched 19 DNA-derived biopharmaceutical products, according to Frost & Sullivan. That's one of the reasons the market-watcher recently bestowed the 2011 Frost & Sullivan Europe Competitive Strategy Leadership Award in Bio Pharmaceutical Contract Manufacturing to the drugmaker.

"The biggest competitive assets of B-I include its strong R&D portfolio with a well-defined in-house biologics pipeline," says research analyst Aiswariya Chidambaram, via email. That pipeline spans "key therapeutic areas and the proprietary technologies for the development of high-titer processes and high-throughput screening methods in mammalian and microbial contract manufacturing."

Among B-I's biopharma credits are inflammatory-disease treatment Enbrel, for Amgen and Pfizer/Wyeth; respiratory infection drug Synagis, for MedImmune; multiple sclerosis treatment Betaferon/Betaseron, for Bayer Health Care; and cancer treatment Erbitux, for Merck Serono.

- see the Boehringer biosimilars release
- here's the Frost & Sullivan award announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.